Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era
| العنوان: | Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era |
|---|---|
| المؤلفون: | Hanne Kuitunen, Marjukka Pollari, Milla E.L. Kuusisto, Peeter Karihtala, Jyrki Jauhiainen, Eija Korkeila, Roosa Enni Inkeri Prusila, Taru Tanhua, Sakari Kakko, Petteri Salmi, Aleksi Postila, Juan-Manuel Sancho, Esa Jantunen, Kaija Vasala, Taina Turpeenniemi-Hujanen, Outi Kuittinen, Santiago Mercadal, Ilja Nystrand, Susanna Tikkanen, Marc Sorigue |
| المصدر: | British Journal of Haematology. 187:364-371 |
| بيانات النشر: | Wiley, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Male, Oncology, medicine.medical_specialty, Adolescent, Follicular lymphoma, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, In patient, Registries, Lymphoma, Follicular, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Incidence (epidemiology), Late effect, Neoplasms, Second Primary, Retrospective cohort study, Hematology, Middle Aged, medicine.disease, Confidence interval, Survival Rate, Standardized mortality ratio, Hematologic Neoplasms, 030220 oncology & carcinogenesis, Female, Rituximab, medicine.symptom, business, Follow-Up Studies, 030215 immunology, medicine.drug |
| الوصف: | Follicular lymphoma (FL) is the most common indolent lymphoma. Currently there are many comparable treatment options available for FL. When selecting the most optimal therapy it is important to consider possible late effects of the treatment as well as survival. Secondary haematological malignancy (SHM) is a severe late effect of treatments, but the incidence of SHMs is still largely unknown. The goal of the present study was to determine the incidence of SHMs and how therapeutic decisions interfere with this risk. The study included 1028 FL patients with a median follow-up time of 5·6 years. The 5-year risk of SHM was 1·1% and the risk was associated with multiple lines of treatment (P = 0·016). The 5-year risk of SHM was 0·5% after the first-line treatment and 1·6% after the second-line. The standardized incidence ratio (SIR) was 6·2 (95% confidence interval 3·4-10·5) for SHM overall. This retrospective study found that the risk of SHM was low after first-line treatment in FL patients from the rituximab era. However, the risk of SHM increases with multiple lines of treatment. Therapeutic approaches should aim to achieve as long a remission as possible with first-line treatment, thereby postponing the added risk of SHM. |
| تدمد: | 1365-2141 0007-1048 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fab2ab1e0caa59dee30edc5be26d40eTest https://doi.org/10.1111/bjh.16090Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4fab2ab1e0caa59dee30edc5be26d40e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652141 00071048 |
|---|